Recurrence of high‐risk bladder cancer: A population‐based analysis

Patients with bladder cancer are apt to develop multiple recurrences that require intervention. The recurrence, progression, and bladder cancer–related mortality rates were examined in a cohort of individuals with high‐grade non–muscle‐invasive bladder cancer.

[1]  E. Feuer,et al.  SEER Cancer Statistics Review, 1975-2003 , 2006 .

[2]  David C. Miller,et al.  Establishment of a urological surgery quality collaborative. , 2010, The Journal of urology.

[3]  P. Abel,et al.  Should pT1 transitional cell cancers of the bladder still be classified as superficial? , 1988, British journal of urology.

[4]  David C. Miller,et al.  Regional collaboration to improve radiographic staging practices among men with early stage prostate cancer. , 2011, The Journal of urology.

[5]  M. Litwin,et al.  Compliance with guidelines for patients with bladder cancer , 2011, Cancer.

[6]  John T. Wei,et al.  Aggressive treatment for bladder cancer is associated with improved overall survival among patients 80 years old or older. , 2004, Urology.

[7]  J Alfred Witjes,et al.  Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. , 2006, European urology.

[8]  E. H. Lambert,et al.  The increasing use of intravesical therapies for stage T1 bladder cancer coincides with decreasing survival after cystectomy , 2007, BJU international.

[9]  David C. Miller,et al.  Understanding the use of immediate intravesical chemotherapy for patients with bladder cancer. , 2012, The Journal of urology.

[10]  J. Gore,et al.  Mortality increases when radical cystectomy is delayed more than 12 weeks , 2009, Cancer.

[11]  F. Algaba,et al.  Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. , 2000, The Journal of urology.

[12]  D. C. Henckel,et al.  Case report. , 1995, Journal.

[13]  S. Loening,et al.  Superficial bladder cancer: progression and recurrence. , 1983, The Journal of urology.

[14]  K. Chamie,et al.  Compliance with guidelines for patients with bladder cancer: variation in the delivery of care , 2011 .

[15]  John T. Wei,et al.  The regionalization of radical cystectomy to specific medical centers. , 2005, The Journal of urology.

[16]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.

[17]  P. Carroll,et al.  Sequential intravesical gemcitabine and mitomycin C chemotherapy regimen in patients with non-muscle invasive bladder cancer. , 2010, Urologic oncology.

[18]  D. Penson,et al.  Predictors of intravesical therapy for nonmuscle invasive bladder cancer: results from the surveillance, epidemiology and end results program 2003 patterns of care project. , 2008, The Journal of urology.

[19]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[20]  E. Holmberg,et al.  The importance of the depth of invasion in stage T1 bladder carcinoma: a prospective cohort study. , 1997, The Journal of urology.

[21]  D. Bajorin,et al.  Defining optimal therapy for muscle invasive bladder cancer. , 2007, The Journal of urology.

[22]  G. Jakse,et al.  Stage T1, grade 3 transitional cell carcinoma of the bladder: an unfavorable tumor? , 1987, The Journal of urology.

[23]  J L Warren,et al.  Development of a comorbidity index using physician claims data. , 2000, Journal of clinical epidemiology.

[24]  E. Messing,et al.  Treatment of nonmuscle invading bladder cancer: Do physicians in the United States practice evidence based medicine? , 2009, Cancer.

[25]  H. Herr,et al.  Tumour progression and survival in patients with T1G3 bladder tumours: 15-year outcome. , 1997, British journal of urology.

[26]  Brian J. Smith,et al.  The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy. , 2006, The Journal of urology.

[27]  E. Guadagnoli,et al.  Patient Demographic and Socioeconomic Characteristics in the SEER-Medicare Database: Applications and Limitations , 2002, Medical care.

[28]  K. Chamie,et al.  Cystectomy in the elderly: does the survival benefit in younger patients translate to the octogenarians? , 2008, BJU international.

[29]  C. Cordon-Cardo,et al.  Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. , 1993, Journal of the National Cancer Institute.

[30]  S. Johansson,et al.  The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years. , 1995, The Journal of urology.

[31]  S. Levitus,et al.  US Government Printing Office , 1998 .

[32]  Deborah Schrag,et al.  Overview of the SEER-Medicare Data: Content, Research Applications, and Generalizability to the United States Elderly Population , 2002, Medical care.

[33]  Claude M Setodji,et al.  Quality of care in patients with bladder cancer , 2012, Cancer.

[34]  F. Debruyne,et al.  Grading in superficial bladder cancer. (1). Morphological criteria. , 1988, British journal of urology.

[35]  E. Ward,et al.  Treatment of muscle invasive bladder cancer: evidence from the National Cancer Database, 2003 to 2007. , 2011, The Journal of urology.